PCN Insights, News, Videos, and More

When co-initiated with an antidepressant, the investigational drug zuranolone significantly reduced depressive symptoms in patients with MDD within 3 days compared with placebo, Sage and Biogen announced.

The US Food and Drug Administration recently issued an alert to healthcare professionals regarding potential risks associated with the use of compounded ketamine nasal spray, which is not FDA-approved and has not been evaluated by the...

A 2-injection start regimen of aripiprazole LAI showed good efficacy and tolerability in a 16-year-old adolescent with schizophrenia, according to a recent case report.

AbbVie has submitted a new drug application (NDA) for cariprazine (VRAYLAR®) to the US Food and Drug Administration (FDA) for the adjunctive treatment of major depressive disorder (MDD) in patients who are receiving ongoing antidepressant...

The American Medical Association and Manatt Health have collaborated on a report that presents ways in which stakeholders can expand access to treatment digitally through behavioral and physical care integration.

Scores on the Computerized Adaptive Test Suicide Scale (CAT-SS) were strongly associated with future suicide-related outcomes in US veterans over 12 months, according to study results published online in PLoS One.

Sana Symposium Steering Committee Members, Lynn-Marie Morski, MD, JD, and Rosalind Watts, MD, named 2 of the 16 most influential women in the psychedelic space.

Outpatient mental health and substance use visits among physicians increased substantially during the first year of the COVID-19 pandemic, according to a population-level cohort study of physicians in Ontario, Canada. Researchers published...